Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

LEXINGTON, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. VYGR, a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead development candidate for its superoxide dismutase 1 (SOD1)-mutated…#lexington #mass #als #voyager #sod1 #iv #tracer #voyagersod1als #g93a #alfredwsandrock
Source: Reuters: Health - Category: Consumer Health News Source Type: news